Operator of a radiopharmaceutical company intended to improve the diagnosis and treatment of metastatic cancer. The company develops imaging and therapeutic molecules for solid and hematologic malignancies by using proprietary technology, enabling patients to receive differentiated molecules with the potential to meaningfully extend their lives with favorable safety profiles.